Repligen (NASDAQ:RGEN) Updates FY 2024 Earnings Guidance

Repligen (NASDAQ:RGEN – Get Free Report) issued an update on its FY 2024 earnings guidance on Wednesday morning. The company provided earnings per share (EPS) guidance of 1.420-1.490 for the period, compared to the consensus estimate of 1.460. The company issued revenue guidance of $620.0 million-$650.0 million, compared to the consensus revenue estimate of $635.6 […]

Related Keywords

United States ,America ,James Bylund ,Asia Pacific ,Ralf Kuriyel ,Stifel Nicolaus ,Keycorp ,Jpmorgan Chase Co ,Repligen Corporation ,Securities Exchange Commission ,Get Free Report ,Moderate Buy ,Exchange Commission ,North America ,Repligen Daily ,Repligen ,Nasdaq Rgen ,Rgen ,Medical ,75991610 ,Guidance ,Earnings ,Preannouncement ,